EUVIMEDEUVIMED entdecken
Crossref

Active management of third stage of labour: methyl ergometrine versus oxytocin

{"name":"Pallala Swarnamukhi","email":"pallalaswarnamukhi0@gmail.com","affili, {"name":"Ponguru Lakshmi Priya","email":"pallalaswarnamukhi0@gmail.com","affi, {"name":"S Pradeep","email":"pallalaswarnamukhi0@gmail.com","affiliatio

International Journal of Experimental and Biomedical Research · 02.07.2026 · 5 (3) · 1-10

DOI: 10.26452/ijebr.v5i3.798 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Experimental and Biomedical Research, online erschienen am 02.07.2026. Verfasst von {"name":"Pallala Swarnamukhi","email":"pallalaswarnamukhi0@gmail.com","affili und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Postpartum hemorrhage (PPH) remains the leading cause of maternal mortality worldwide. Effective prophylactic uterotonic therapy during the third stage of labor is essential for reducing maternal morbidity and mortality, as nearly two - thirds of PPH cases o ccur in women without identifiable risk factors. This randomized comparative study included 400 term pregnant women undergoing vaginal delivery at the labor ward of PESIMSR Hospital. Participants were randomly allocated into two groups: Group I (n = 200) r eceived intramuscular oxytocin, while Group II (n = 200) received intravenous methylergometrine within one minute of delivery. Primary outcomes included blood loss during the third stage of labor, duration of the third stage, changes in hemoglobin and hema tocrit levels, need for additional uterotonics, and adverse effects. Mean blood loss was significantly lower in the methylergometrine group (148.9 mL) than in the oxytocin group (172.8 mL) (P < 0.05). Methylergometrine also shortened the third stage of lab or, improved hematological outcomes, and reduced the need for additional uterotonics. However, it was associated with a higher incidence of hypertension, nausea, and vomiting. Overall, methylergometrine demonstrated greater efficacy than oxytocin but with increased adverse effects.

Zitieren

APA

Swarnamukhi","email":"pallalaswarnamukhi0@gmail.com","affili, N., Priya","email":"pallalaswarnamukhi0@gmail.com","affi, N. L., & Pradeep","email":"pallalaswarnamukhi0@gmail.com","affiliatio, N. (2026). Active management of third stage of labour: methyl ergometrine versus oxytocin. International Journal of Experimental and Biomedical Research, 5(3), 1-10. https://doi.org/10.26452/ijebr.v5i3.798

Vancouver

Swarnamukhi","email":"pallalaswarnamukhi0@gmail.com","affili N, Priya","email":"pallalaswarnamukhi0@gmail.com","affi NL, Pradeep","email":"pallalaswarnamukhi0@gmail.com","affiliatio N. Active management of third stage of labour: methyl ergometrine versus oxytocin. International Journal of Experimental and Biomedical Research. 2026;5(3):1-10. doi:10.26452/ijebr.v5i3.798

BibTeX
@article{Swarnamukhiemailpallalaswarnamukhigmailcomaffili2026,
  author = {Swarnamukhi","email":"pallalaswarnamukhi0@gmail.com","affili, "name":"Pallala and Priya","email":"pallalaswarnamukhi0@gmail.com","affi, "name":"Ponguru Lakshmi and Pradeep","email":"pallalaswarnamukhi0@gmail.com","affiliatio, "name":"S},
  title = {Active management of third stage of labour: methyl ergometrine versus oxytocin},
  journal = {International Journal of Experimental and Biomedical Research},
  year = {2026},
  volume = {5},
  number = {3},
  pages = {1--10},
  doi = {10.26452/ijebr.v5i3.798}
}
Kostenlos starten →